Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prescription Digital Therapeutics

tijana being interviewed

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

Genesis Research Group

- PMLiVE

FDA approves Geron’s Rytelo to treat lower-risk myelodysplastic syndrome patients

The oligonucleotide telomerase inhibitor is administered as an intravenous infusion every four weeks

- PMLiVE

Bristol Myers Squibb’s Breyanzi receives FDA approval for mantle cell lymphoma

The rare form of non-Hodgkin lymphoma accounts for around 3% of all NHL cases

- PMLiVE

Moderna’s RSV vaccine mRESVIA granted FDA approval for use in older adults

The approval marks the first time an mRNA vaccine has been approved for a disease other than COVID-19

- PMLiVE

Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...

Research Partnership

- PMLiVE

Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti

The biosimilars have been authorised for all indications covered by Amgen's reference medicines

- PMLiVE

Sandoz separates from Novartis as an independent spin-off company

The split allows Sandoz to strengthen its position in generics and biosimilars

- PMLiVE

Sandoz biosimilar receives EC approval to treat MS

Tyruko is the first and only biosimilar treatment for relapsing-remitting MS in Europe

- PMLiVE

Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis

The disease-modifying therapy is approved to treat all indications covered by Tysabri

- PMLiVE

Sandoz granted positive CHMP opinion for multiple sclerosis biosimilar

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Sandoz launches high-concentration biosimilar of AbbVie’s Humira in the US

Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

- PMLiVE

Sandoz and Just-Evotec Biologics announce multi-year biosimilar partnership

The Novartis unit will aim to expand its current pipeline of biosimilars to about 24 candidates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links